רופרון -אי 6 מ.י./0.5 מ"ל

Country: Israel

Language: Hebrew

Source: Ministry of Health

Active ingredient:

INTERFERON ALFA 2A 6 MIU / 0.5 ML

Available from:

ROCHE PHARMACEUTICALS (ISRAEL) LTD

ATC code:

L03AB04

Pharmaceutical form:

SOLUTION FOR INJECTION

Administration route:

S.C

Manufactured by:

HOFFMANN LA ROCHE, SWITZERLAND

Therapeutic group:

INTERFERON ALFA-2A

Therapeutic indications:

Roferon-A is indicated for the treatment of:- Condylomata acuminata - Hairy cell leukaemia.- AIDS patients with progressive, asymptomatic Kaposi's sarcoma who have a CD4 count > 250/mm3.- Chronic phase Philadelphia-chromosome positive chronic myelogenous leukaemia. Roferon-A is not an alternative treatment for CML patients who have an HLA-identical relative and for whom allogeneic bone marrow transplantation is planned or possible in the immediate future. It is still unknown whether Roferon-A can be considered as a treatment with a curative potential in this indication.- Adult patients with histologically proven chronic hepatitis B who have markers for viral replication, i.e., those who are positive for HBV DNA or HBeAg.- Adult patients with histologically proven chronic hepatitis C who are positive for HCV antibodies or HCV RNA and have elevated serum alanine aminotransferase (ALT) without liver decompensation.- Follicular non-Hodgkin’s lymphoma.- Advanced renal cell carcinoma.- Patients with AJCC stage II m

Authorization date:

2012-12-01